Mixed Endometrial Epithelial Carcinoma: Epidemiology, Treatment and Survival Rates—A 10-Year Retrospective Cohort Study from a Single Institution
Mixed endometrial carcinoma (MEEC) refers to rare endometrial tumours that are composed of two or more distinct histotypes, at least one of which is serous or clear cell. The aim of this study was to evaluate the epidemiology, treatment outcomes and survival rates of patients with mixed endometrial...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-10-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/12/19/6373 |
| _version_ | 1797575590011731968 |
|---|---|
| author | Christina Pappa Valentina Le Thanh Sarah Louise Smyth Andreas Zouridis Ammara Kashif Negin Sadeghi Alisha Sattar Stephen Damato Mostafa Abdalla Antonio Simone Laganà Federico Ferrari Sean Kehoe Susan Addley Hooman Soleymani majd |
| author_facet | Christina Pappa Valentina Le Thanh Sarah Louise Smyth Andreas Zouridis Ammara Kashif Negin Sadeghi Alisha Sattar Stephen Damato Mostafa Abdalla Antonio Simone Laganà Federico Ferrari Sean Kehoe Susan Addley Hooman Soleymani majd |
| author_sort | Christina Pappa |
| collection | DOAJ |
| description | Mixed endometrial carcinoma (MEEC) refers to rare endometrial tumours that are composed of two or more distinct histotypes, at least one of which is serous or clear cell. The aim of this study was to evaluate the epidemiology, treatment outcomes and survival rates of patients with mixed endometrial carcinoma. The medical records of 34 patients diagnosed with MEEC between March 2010 and January 2020 were reviewed retrospectively. Clinicopathological variables and treatment strategies were assessed, and overall survival and disease-free survival rates were evaluated. The histology of endometrioid and serous component was found in 26 (76.5%) patients, followed by serous and clear-cell components (5/34, 14.5%) and mixed endometrioid serous and clear-cell components (3/34, 8.8%). The median age at diagnosis was 70 years (range 52–84), and the median follow-up time was 55 months. The 5-year disease-free survival and the 5-year overall survival were 50.4% and 52.4%, respectively. Advanced disease stage was identified as an independent predictor of inferior disease-free (<0.003) and overall survival (<i>p</i> < 0.001). Except for stage, none of the traditional prognostic factors was associated with disease recurrence or death from disease. MEECs represent rare high-risk endometrial carcinomas with significant diagnostic and treatment challenges. Undoubtedly, the implementation of a molecular analysis can offer further diagnostic and management insights. |
| first_indexed | 2024-03-10T21:41:36Z |
| format | Article |
| id | doaj.art-3b2751b2dbbe4a418a8c701b78c35155 |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-10T21:41:36Z |
| publishDate | 2023-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-3b2751b2dbbe4a418a8c701b78c351552023-11-19T14:37:53ZengMDPI AGJournal of Clinical Medicine2077-03832023-10-011219637310.3390/jcm12196373Mixed Endometrial Epithelial Carcinoma: Epidemiology, Treatment and Survival Rates—A 10-Year Retrospective Cohort Study from a Single InstitutionChristina Pappa0Valentina Le Thanh1Sarah Louise Smyth2Andreas Zouridis3Ammara Kashif4Negin Sadeghi5Alisha Sattar6Stephen Damato7Mostafa Abdalla8Antonio Simone Laganà9Federico Ferrari10Sean Kehoe11Susan Addley12Hooman Soleymani majd13Department of Gynaecological Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 7LE, UKDepartment of Gynaecological Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 7LE, UKDepartment of Gynaecological Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 7LE, UKDepartment of Gynaecological Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 7LE, UKDepartment of Gynaecological Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 7LE, UKDepartment of Gynaecological Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 7LE, UKDepartment of Gynaecological Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 7LE, UKDepartment of Gynaecological Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 7LE, UKGynaecology—Guy’s and St Thomas’ NHS Foundation Trust, London SE1 9RT, UKUnit of Obstetrics and Gynecology, “Paolo Giaccone” Hospital, Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, 90127 Palermo, ItalyDepartment of Clinical and Experimental Sciences, University of Brescia, 25136 Brescia, ItalyDepartment of Gynaecological Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 7LE, UKDepartment of Gynaecological Oncology, University Hospitals of Derby and Burton NHS Foundation Trust, Derby DE22 3NE, UKDepartment of Gynaecological Oncology, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 7LE, UKMixed endometrial carcinoma (MEEC) refers to rare endometrial tumours that are composed of two or more distinct histotypes, at least one of which is serous or clear cell. The aim of this study was to evaluate the epidemiology, treatment outcomes and survival rates of patients with mixed endometrial carcinoma. The medical records of 34 patients diagnosed with MEEC between March 2010 and January 2020 were reviewed retrospectively. Clinicopathological variables and treatment strategies were assessed, and overall survival and disease-free survival rates were evaluated. The histology of endometrioid and serous component was found in 26 (76.5%) patients, followed by serous and clear-cell components (5/34, 14.5%) and mixed endometrioid serous and clear-cell components (3/34, 8.8%). The median age at diagnosis was 70 years (range 52–84), and the median follow-up time was 55 months. The 5-year disease-free survival and the 5-year overall survival were 50.4% and 52.4%, respectively. Advanced disease stage was identified as an independent predictor of inferior disease-free (<0.003) and overall survival (<i>p</i> < 0.001). Except for stage, none of the traditional prognostic factors was associated with disease recurrence or death from disease. MEECs represent rare high-risk endometrial carcinomas with significant diagnostic and treatment challenges. Undoubtedly, the implementation of a molecular analysis can offer further diagnostic and management insights.https://www.mdpi.com/2077-0383/12/19/6373mixed endometrial carcinomahigh graderecurrenceclear cellseroussurvival |
| spellingShingle | Christina Pappa Valentina Le Thanh Sarah Louise Smyth Andreas Zouridis Ammara Kashif Negin Sadeghi Alisha Sattar Stephen Damato Mostafa Abdalla Antonio Simone Laganà Federico Ferrari Sean Kehoe Susan Addley Hooman Soleymani majd Mixed Endometrial Epithelial Carcinoma: Epidemiology, Treatment and Survival Rates—A 10-Year Retrospective Cohort Study from a Single Institution Journal of Clinical Medicine mixed endometrial carcinoma high grade recurrence clear cell serous survival |
| title | Mixed Endometrial Epithelial Carcinoma: Epidemiology, Treatment and Survival Rates—A 10-Year Retrospective Cohort Study from a Single Institution |
| title_full | Mixed Endometrial Epithelial Carcinoma: Epidemiology, Treatment and Survival Rates—A 10-Year Retrospective Cohort Study from a Single Institution |
| title_fullStr | Mixed Endometrial Epithelial Carcinoma: Epidemiology, Treatment and Survival Rates—A 10-Year Retrospective Cohort Study from a Single Institution |
| title_full_unstemmed | Mixed Endometrial Epithelial Carcinoma: Epidemiology, Treatment and Survival Rates—A 10-Year Retrospective Cohort Study from a Single Institution |
| title_short | Mixed Endometrial Epithelial Carcinoma: Epidemiology, Treatment and Survival Rates—A 10-Year Retrospective Cohort Study from a Single Institution |
| title_sort | mixed endometrial epithelial carcinoma epidemiology treatment and survival rates a 10 year retrospective cohort study from a single institution |
| topic | mixed endometrial carcinoma high grade recurrence clear cell serous survival |
| url | https://www.mdpi.com/2077-0383/12/19/6373 |
| work_keys_str_mv | AT christinapappa mixedendometrialepithelialcarcinomaepidemiologytreatmentandsurvivalratesa10yearretrospectivecohortstudyfromasingleinstitution AT valentinalethanh mixedendometrialepithelialcarcinomaepidemiologytreatmentandsurvivalratesa10yearretrospectivecohortstudyfromasingleinstitution AT sarahlouisesmyth mixedendometrialepithelialcarcinomaepidemiologytreatmentandsurvivalratesa10yearretrospectivecohortstudyfromasingleinstitution AT andreaszouridis mixedendometrialepithelialcarcinomaepidemiologytreatmentandsurvivalratesa10yearretrospectivecohortstudyfromasingleinstitution AT ammarakashif mixedendometrialepithelialcarcinomaepidemiologytreatmentandsurvivalratesa10yearretrospectivecohortstudyfromasingleinstitution AT neginsadeghi mixedendometrialepithelialcarcinomaepidemiologytreatmentandsurvivalratesa10yearretrospectivecohortstudyfromasingleinstitution AT alishasattar mixedendometrialepithelialcarcinomaepidemiologytreatmentandsurvivalratesa10yearretrospectivecohortstudyfromasingleinstitution AT stephendamato mixedendometrialepithelialcarcinomaepidemiologytreatmentandsurvivalratesa10yearretrospectivecohortstudyfromasingleinstitution AT mostafaabdalla mixedendometrialepithelialcarcinomaepidemiologytreatmentandsurvivalratesa10yearretrospectivecohortstudyfromasingleinstitution AT antoniosimonelagana mixedendometrialepithelialcarcinomaepidemiologytreatmentandsurvivalratesa10yearretrospectivecohortstudyfromasingleinstitution AT federicoferrari mixedendometrialepithelialcarcinomaepidemiologytreatmentandsurvivalratesa10yearretrospectivecohortstudyfromasingleinstitution AT seankehoe mixedendometrialepithelialcarcinomaepidemiologytreatmentandsurvivalratesa10yearretrospectivecohortstudyfromasingleinstitution AT susanaddley mixedendometrialepithelialcarcinomaepidemiologytreatmentandsurvivalratesa10yearretrospectivecohortstudyfromasingleinstitution AT hoomansoleymanimajd mixedendometrialepithelialcarcinomaepidemiologytreatmentandsurvivalratesa10yearretrospectivecohortstudyfromasingleinstitution |